#China #New York City #biopharmaceuticals #Everest Medicines #Hong Kong Stock Exchange

Everest Medicines to Participate in September Investor Conferences

Everest Medicines, a prominent biopharmaceutical firm listed on the Hong Kong Stock Exchange, has announced its participation in two major investor conferences lined up for September 2025. This opportunity will see President and Chief Financial Officer Ian Woo attend the events in New York City, showcasing the company's commitment to engaging with investors and stakeholders in the healthcare sector.

Conference Details

The following are the details of the conferences where Ian Woo will be presenting:

1. Morgan Stanley 23rd Annual Global Healthcare Conference
- Date: Monday, September 8, 2025
- Format: Fireside chat and one-on-one meetings
- Time: 5:35 PM ET
- Location: New York, NY

2. H.C. Wainwright 27th Annual Global Investment Conference
- Date: Wednesday, September 10, 2025
- Format: In-person presentation and one-on-one meetings
- Time: 8:00 AM ET
- Location: New York, NY

These conferences present an excellent platform for Everest Medicines to highlight its innovative approaches and advancements in healthcare, particularly regarding the unmet medical needs in Asian markets.

About Everest Medicines

Founded with a mission to transform therapeutic landscapes, Everest Medicines focuses on the discovery and development of innovative medical solutions. The company’s portfolio boasts potentially groundbreaking pharmaceutical products, particularly in the fields of renal diseases, infectious diseases, and autoimmune disorders. The management team, rich in expertise from both global and local pharmaceutical landscapes, ensures a strategic approach to product development, which includes conducting high-quality discovery, clinical development, and regulatory affairs.

The firm aims to address critical medical needs through first-in-class or best-in-class therapeutic options. Its commitment to enhancing patient health outcomes in Asia positions Everest Medicines as a leader in the biopharmaceutical industry, dedicated to advancing healthcare solutions.

As the investor conferences approach, stakeholders will be keen to gain insights into Everest Medicines’ strategic vision, future developments, and the progress of their clinical portfolios. With a robust presentation lined up, the company's management is poised to clearly communicate their ongoing commitment to innovation in drug development.

Conclusion

The upcoming conferences are not just an opportunity for Everest Medicines to showcase its advancements; they are also a testament to its focus on improving global health. As Everest Medicines seeks to expand its reach and innovate in the pharmaceutical sector, these events will be essential in solidifying relationships with investors and paving the way for future collaborations. For more information about Everest Medicines and their initiatives, you can visit their official website at www.everestmedicines.com.